Previous close | 0.0130 |
Open | 0.0170 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0170 - 0.0206 |
52-week range | 0.0125 - 0.1083 |
Volume | |
Avg. volume | 42,780 |
Market cap | 6.483M |
Beta (5Y monthly) | 0.96 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0380 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Elixinol, hemp-derived CBD brand and industry veteran, announced today the launch of two new innovative CBD products focused on supporting sleep*. Elixinol's Sleep Rapid Rest Liposome and Sleep Gummies are unique, melatonin-free options for consumers to support optimal sleep. Both products include CBN, marking a first for the brand to include a minor cannabinoid into product formulations. The new product additions also coincide with the brand's new '2022 & You' wellness campaign, encouraging con
Elixinol Wellness Limited (Elixinol or the Company) (ASX:EXL; OTCQB:ELLXF) is pleased to communicate that Assembly Bill 45 (AB45) was signed into law by Californian Governor, Mr Gavin Newsom on 6 October 2021, establishing a comprehensive regulatory framework for the manufacture and retail sale of products in California containing hemp derived cannabidiol (CBD), including dietary supplements, topicals, over-the-counter, and pet products, among others.
Elixinol, a global hemp-derived CBD brand and industry veteran, introduced its first line of pet products. The new collection is specifically formulated for dogs and includes a bacon-flavored tincture and two functionally focused CBD dog chews targeting specific benefits. The collection is available now on Elixinol.com.